Slide 1: Second Quarter 2025 Financial Results & Business Update
Second Quarter 2025 Financial Results & Business Update July 29, 2025
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Q2 2025 Financial and Operational Performance
Q2 2025 Financial and Operational Performance
Slide 4: Q2 2025 Financial Results Summary
Q2 2025 Financial Results Summary Total Revenue GAAP Net Income GAAP Earnings Per Share Diluted In millions In millions $399.1 $390.7 $91.4 $0.53 $0.52 $87.1 Q2 2024 Q2 2025 Q2 2024 Q2 2025 Q2 2024 Q2 2025 Q2 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August
Slide 5: Q2 2025 Profitability
Q2 2025 Profitability GAAP Net Income EBITDA* Adjusted EBITDA* From Continuing Operations From Continuing Operations In millions In millions In millions $94.7 $118.6 $135.3 $87.1 $126.5 $101.6 Q2 2024 Q2 2025 Q2 2024 Q2 2025 Q2 2024 Q2 2025 EBITDA represents earnings before interest, tax, depreciati
Slide 6: Q2 2025 Revenue Summary
Q2 2025 Revenue Summary In millions Q2’25 Q2’24 Total Proprietary Net Sales $307.2 $269.3 VIVITROL® $121.7 $111.9 ARISTADA®* $101.3 $86.0 LYBALVI® $84.3 $71.4 Manufacturing & Royalty Revenue $83.4** $129.9 Total Revenue $390.7** $399.1 Amounts in the table may not sum due to rounding. *Inclusive of
Slide 7: Alkermes: 2025 Financial Expectations
Alkermes: 2025 Financial Expectations* Financial Expectations for (in millions) Year Ending Dec. 31, 2025 Total Revenues $1,340 – $1,430 Expected net sales of proprietary products: COGS $185 – $205 • VIVITROL® net sales of $440M – $460M R&D Expense $305 – $335 • ARISTADA®i net sales of $335M – $355M
Slide 8: Q2 2025 Commercial Review
Q2 2025 Commercial Review
Slide 9: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) $90 Q2’25 LYBALVI net sales of $84.3M reflects 18% growth compared to Q2’24 $80 • Q2’25 gross-to-net deductions: ~29% $70 $60 Outlook: $50 • FY’25 net sales expected to range from $320M – $340M* $40 $30 $20 $10 $0 Q1'23 Q2'23 Q3'
Slide 10: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) $110 Q2’25 ARISTADA net sales were $101.3M $100 Outlook: $90 • FY’25 net sales expected to range from $80 $335M – $355M†* $70 $60 $50 $40 $30 $20 $10 $0 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 *Inclusive of
Slide 11: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) $140 Q2’25 VIVITROL net sales were $121.7M $120 Outlook: • FY’25 net sales expected to range from $100 $440M – $460M* $80 $60 $40 $20 $0 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 *These expectations were initi
Slide 12: Appendix
Appendix
Slide 13: Appendix: Amounts Included in Discontinued Operations
Appendix: Amounts Included in Discontinued Operations Three Months Ended (In thousands) June 30, 2024 Cost of goods manufactured and sold $ -- Research and development 3,913 Selling, general and administrative --- Income tax benefit $ (613) Loss from discontinued operations, net of tax $ 3,300 13 ©
Slide 14: Appendix: Financial Results GAAP to Non-GAAP Reconciliation
Appendix: Financial Results GAAP to Non-GAAP Reconciliation Three Months Ended Three Months Ended (In millions) June 30, 2025 June 30, 2024 Net Income from Continuing Operations — GAAP $ 87.1 $ 94.7 Adjustments: Depreciation and amortization expense 7.8 6.7 Interest income (11.1) (10.7) Interest exp
Slide 15: Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation
Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Year Ending (In millions) December 31, 2025 Projected Net Income — GAAP $ 190.0 Adjustments: Net interest income (30.0) Depreciation and amortization expense 30.0 Provision for income taxes 40.0 Projected EBTIDA $ 230.0 Shared-based co
Slide 16: www.alkermes.com
www.alkermes.com © 2025 Alkermes. All rights reserved.